Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
Adicet公司已經開始招募轉移性/愛文思控股晚期腎透明細胞癌ADI-270第1期臨床試驗；首個具有潛力應對實體腫瘤並進入臨床試驗的Gamma Delta CAR T細胞療法；初步第1期臨床試驗...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025
艾切託開放對轉移性/愛文思控股透明細胞腎細胞癌的ADI-270第一階段臨床試驗的招募；首個有潛力解決實體腫瘤的伽馬δ CAR t 電芯療法進入臨床試驗；初步第一階段臨床數據預計在2025年上半年發佈。
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
首個有潛力解決實體腫瘤的伽馬δ CAR t 電芯療法進入臨床試驗。
Preliminary Phase 1 clinical data expected in the first half of 2025
初步第一階段臨床數據預計在2025年上半年發佈。
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
艾切託公司（納斯達克：ACET）是一家臨床階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ t 電芯療法，今天宣佈對轉移性/愛文思控股透明細胞腎細胞癌（ccRCC）患者進行ADI-270第一階段臨床試驗的招募已開啓。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間